Neurelis, Inc. today announced the acquisition of Aegis Therapeutics, a San Diego-based drug delivery technology company. Aegis Therapeutics’ proprietary portfolio includes Intravail®, ProTek® and Hydrogel™, three non-invasive drug delivery and stabilization technologies applicable to a wide-range of molecules including therapeutic proteins, peptides, non-peptide macromolecules and small molecules.
VALTOCO™ (diazepam nasal spray), Neurelis’ lead product candidate, is a proprietary formulation of diazepam incorporating the unique combination of a vitamin E-based solution with Aegis’ Intravail® transmucosal absorption enhancement technology. Intravail® has been shown to increase absorption and reduce variability of drugs when incorporated in the formulation, with no known negative impact on safety or tolerability. Neurelis anticipates FDA approval and commercial launch of VALTOCO in 2019.
“We have been very impressed by the performance of Intravail® in VALTOCO as well as other licensed programs initiated by Aegis,” said Neurelis President and CEO Craig Chambliss. “Intravail® is a unique technology platform that we intend to fully integrate into our robust product pipeline which is targeted to address significant unmet needs in neurology.” In addition to VALTOCO, Chambliss said the company’s pipeline includes NRL-2 (a drug candidate being developed as on-hand rescue treatment for intermittent use to control acute anxiety episodes or panic attacks) and NRL-3 (a drug candidate being developed as a non-invasive acute therapy to stop seizures that have progressed to status epilepticus).
Ed Maggio, CEO of Aegis Therapeutics added, “We are thankful to have been a part of the important work in progressing these programs with our strategic partners over the years. In the coming months, we have the potential of seeing the first two products incorporating the Intravail technology approved by the FDA. Given our longstanding relationship with Neurelis and their appreciation for the value of Intravail, we are excited for the next chapters of success with these novel technologies.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Chambliss added that the acquisition of Aegis provides Neurelis an even more robust pipeline, including licensing deals with Dr. Reddy’s Laboratories, Opiant Pharmaceuticals and others. He added that the company is excited to seek additional strategic partnerships for this portfolio of technologies, offering exceptional potential value in enhancing drug development and clinical performance.
Date: December 10, 2018
Source: BizJournals